Work

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

Year: 2020

Type: article

Abstract: To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/h20d-xc88

Authors: Bastow, Barbara, Kim, Peter S., Gallien, Sebastien, Eron, Joseph J., Taiwo, Babafemi, Acosta, Edward P., Wilson, Cara C., Kuritzkes, Daniel R., Matining, Roy M., Zheng, Lu, Berzins, Baiba I.

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: GlaxoSmithKline, National Institutes of Health, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research, National Center for Research Resources

Awards: G650174051, G9000072212

OpenAlex ID: W4299422768

FWCI:

Cites:

Cited by:

Related to: 10